Evaluation of PF-08046049/SGN-BB228 in Patients with Advanced Pancreatic, Colorectal, Non-Small Cell Lung, Mesothelioma, and Cutaneous Melanoma Neoplasms

The primary objective of this study is to evaluate the efficacy and safety of **PF-08046049/SGN-BB228** in patients with advanced **cutaneous melanoma** and other solid tumors, including **pancreatic neoplasms**, **colorectal neoplasms**, **non-small cell lung cancer**, and **mesothelioma**. The clinical relevance of this study lies in its potential to provide new therapeutic options for these malignancies, which are often associated with poor prognosis and limited treatment alternatives.

The clinical trial involves a total of **255 participants** diagnosed with various types of cancer, including **pancreatic neoplasms**, **colorectal neoplasms**, **non-small cell lung cancer**, **mesothelioma**, and **cutaneous melanoma**. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of a novel therapeutic agent in patients with **pancreatic neoplasms**, **colorectal neoplasms**, **non-small cell lung cancer**, **mesothelioma**, and **cutaneous melanoma**. This is a Phase 1 trial, characterized by a **randomized**, **double-blind**, and **controlled** design, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is set to commence recruitment on May 1, 2023, and is anticipated to conclude by October 1, 2028, encompassing a total duration of approximately five years and five months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive medical evaluations and baseline assessments. Following successful inclusion, participants will be scheduled for regular follow-up visits at specified intervals to monitor treatment response, safety, and any adverse events. These visits will include clinical assessments, laboratory tests, and imaging studies as necessary. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is generally anticipated to last throughout the trial duration unless early termination criteria are met. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study period.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of May 1, 2023, and an estimated end date of October 1, 2028. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact. The methods for measuring and analyzing efficacy will adhere to standard clinical trial protocols, ensuring the reliability and validity of the results. The trial's duration and phase indicate an early-stage investigation, focusing on initial assessments of the treatment's effects.